We are pleased to announce the publication of results from the PEPITES (Peanut EPIT Efficacy and Safety) Phase III trial, evaluating the safety and efficacy of investigational Viaskin Peanut in children ages 4 to 11 in @JAMA_current: bit.ly/2GEhrE3
DBV Technologies
520 posts
DBV Technologies
@DBVTechnologies
We are a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy.See our community guidelines: on.fb.me/1L8jVrw
Joined May 2014
- We’re pleased to report positive three-year, long-term data from the PEOPLE Phase III open-label extension study of Viaskin Peanut in children with peanut allergy. Learn more: bit.ly/2Fzro3g
- Live at #EAACI2018: We’re presenting new clinical data on investigational Epicutaneous Immunotherapy #EPIT for #foodallergy. Join us at one of our sessions this week to learn more: goo.gl/kHBrNK #peanutallergy #milkallergy
- May is Food Allergy Awareness Month! Join us in raising awareness for the millions of families impacted by food allergies. #FAAM
- We’re proud to report positive topline results from the Phase 3 EPITOPE trial of Viaskin Peanut in peanut-allergic toddlers. Learn more: bit.ly/3xqGxzl
- Attending #ACAAI18? Dr. Hugh Sampson will be hosting a symposium on important considerations for potential peanut allergy immunotherapies. #foodallergies #peanutallergy
- We are excited to announce the first patient screened in our VITESSE Phase 3 clinical trial in #PeanutAllergic children 4-7 years old. Read more about our trial here: bit.ly/3L6u77i
- We’re pleased to announce that the U.S. FDA accepted our BLA filing for Viaskin Peanut. Learn more: bit.ly/2oUgiAQ
- . @AAAAI_org Annual Meeting 2019 is focused on Food Allergies; we’re looking forward to attending and presenting new data on investigational Epicutaneous Immunotherapy.
- Our EPITOPE trial of Viaskinᵀᴹ Peanut in toddlers with #PeanutAllergy, published in @NEJM, is now available in easy-to-understand language in @fsgimt. Find out more about the results from the editorial called “Good News for Toddlers with Peanut Allergy”: brnw.ch/21wFKzL
- The Journal of Allergy and Clinical Immunology has published results from our three-year, open-label extension of the Phase III PEPITES study (PEOPLE). Read more here: bit.ly/3iJrCXT
- Our Talking Peanut Allergy campaign is about raising awareness of challenges faced by children w/ #peanutallergies & their families. There’s been a 21% increase in diagnoses since 2010. Join the conversation & discover new tips for managing peanut allergy: bit.ly/2CC6oIU
- We’re excited to join our #allergyimmunology community at the virtual #AAAAI21 meeting where we’ll be presenting new data on #EPIT – if you’re attending, be sure to check out our virtual booth (Deluxe Hall A-H) and the FIT Networking Lounge Sponsored by DBV Technologies!
- We are excited to have our EPITOPE Phase 3 trial evaluating our investigational Viaskin Peanut in children 1-3 years published in The New England Journal of Medicine (@NEJM ). Watch below and read the publication here: bit.ly/3BkOd7D
00:00
